Eriko Sumi

896 total citations
31 papers, 691 citations indexed

About

Eriko Sumi is a scholar working on Oncology, Molecular Biology and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Eriko Sumi has authored 31 papers receiving a total of 691 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 6 papers in Molecular Biology and 6 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Eriko Sumi's work include Ethics in Clinical Research (5 papers), Biomedical Ethics and Regulation (4 papers) and Bone health and treatments (4 papers). Eriko Sumi is often cited by papers focused on Ethics in Clinical Research (5 papers), Biomedical Ethics and Regulation (4 papers) and Bone health and treatments (4 papers). Eriko Sumi collaborates with scholars based in Japan, United States and Singapore. Eriko Sumi's co-authors include Hiroshi Kanamori, Atsushi Fukatsu, Toshio Doi, Takeshi Matsubara, Toru Kita, Hidenori Arai, Noriyuki Iehara, Kojiro Nagai, Toshikazu Takahashi and Akira Mima and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Eriko Sumi

30 papers receiving 679 citations

Peers

Eriko Sumi
Eric E. Simon United States
Kuolung Hu United States
Nagaraj Manickam India
An-Hang Yang Taiwan
Wen Si China
Gustavo Aroca Colombia
Michael S. Balzer Germany
Marcelino Bermúdez-López Spain
Hermann Joseph Gröne Germany
Fengxin Zhu China
Eric E. Simon United States
Eriko Sumi
Citations per year, relative to Eriko Sumi Eriko Sumi (= 1×) peers Eric E. Simon

Countries citing papers authored by Eriko Sumi

Since Specialization
Citations

This map shows the geographic impact of Eriko Sumi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eriko Sumi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eriko Sumi more than expected).

Fields of papers citing papers by Eriko Sumi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eriko Sumi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eriko Sumi. The network helps show where Eriko Sumi may publish in the future.

Co-authorship network of co-authors of Eriko Sumi

This figure shows the co-authorship network connecting the top 25 collaborators of Eriko Sumi. A scholar is included among the top collaborators of Eriko Sumi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eriko Sumi. Eriko Sumi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Nomura, Takashi, Eriko Sumi, Gyohei Egawa, et al.. (2021). Safety and Efficacy of FIT039 for Verruca Vulgaris: A Placebo-Controlled, Phase I/II Randomized Controlled Trial. SHILAP Revista de lepidopterología. 1(3). 100026–100026. 1 indexed citations
2.
Sumi, Eriko, et al.. (2020). 2010年から2018年までの3つの調節機関による抗腫瘍薬の試験集団と承認された治療適応の間の差異に関する定性的研究【JST・京大機械翻訳】. Clinical Therapeutics. 42(2). 305–320. 2 indexed citations
3.
Ikeda, Hanako Ohashi, Yuki Muraoka, Masayuki Hata, et al.. (2020). Safety and effectiveness of a novel neuroprotectant, KUS121, in patients with non-arteritic central retinal artery occlusion: An open-label, non-randomized, first-in-humans, phase 1/2 trial. PLoS ONE. 15(2). e0229068–e0229068. 19 indexed citations
4.
Nomura, Takashi, Eriko Sumi, Gyohei Egawa, et al.. (2019). The efficacy of a cyclin dependent kinase 9 (CDK9) inhibitor, FIT039, on verruca vulgaris: study protocol for a randomized controlled trial. Trials. 20(1). 489–489. 4 indexed citations
5.
6.
Ajiro, Masahiko, Hiroyuki Sakai, Hiroshi Onogi, et al.. (2018). CDK9 Inhibitor FIT-039 Suppresses Viral Oncogenes E6 and E7 and Has a Therapeutic Effect on HPV-Induced Neoplasia. Clinical Cancer Research. 24(18). 4518–4528. 30 indexed citations
7.
Sumi, Eriko, Takashi Nomura, Ryuji Uozumi, et al.. (2018). Safety and Plasma Concentrations of a Cyclin-dependent Kinase 9 (CDK9) Inhibitor, FIT039, Administered by a Single Adhesive Skin Patch Applied on Normal Skin and Cutaneous Warts. Clinical Drug Investigation. 39(1). 55–61. 8 indexed citations
8.
Sugie, Tomoharu, Eiji Suzuki, Akira Yamauchi, et al.. (2018). Combined effects of neoadjuvant letrozole and zoledronic acid on γδT cells in postmenopausal women with early-stage breast cancer. The Breast. 38. 114–119. 9 indexed citations
9.
Yamazaki, Tōru, Masashi Yamori, Shiro Tanaka, et al.. (2013). Risk Factors and Indices of Osteomyelitis of the Jaw in Osteoporosis Patients: Results from a Hospital-Based Cohort Study in Japan. PLoS ONE. 8(11). e79376–e79376. 4 indexed citations
10.
Yamamoto, Keiichi, Eriko Sumi, Tōru Yamazaki, et al.. (2012). A pragmatic method for electronic medical record-based observational studies: developing an electronic medical records retrieval system for clinical research. BMJ Open. 2(6). e001622–e001622. 16 indexed citations
11.
Yamazaki, Tōru, Masashi Yamori, Keiichi Yamamoto, et al.. (2012). Risk of osteomyelitis of the jaw induced by oral bisphosphonates in patients taking medications for osteoporosis: A hospital-based cohort study in Japan. Bone. 51(5). 882–887. 30 indexed citations
12.
Sumi, Eriko, Toshinori Murayama, Masafumi Kitakaze, et al.. (2011). A Multi-institutional Descriptive Study on the Methods of Subject Recruitment for Clinical Trials. Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics. 42(1). 27–31.
13.
Murayama, Toshinori, et al.. (2011). Trend Analysis of Research on Informed Consent in Clinical Trials: Comprehensive Retrieval via Electronic Databases. Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics. 42(1). 21–25. 1 indexed citations
14.
Sumi, Eriko, Toshinori Murayama, & Masayuki Yokode. (2009). A survey of attitudes toward clinical research among physicians at Kyoto University Hospital. BMC Medical Education. 9(1). 75–75. 37 indexed citations
15.
Kanamori, Hiroshi, Takeshi Matsubara, Akira Mima, et al.. (2007). Inhibition of MCP-1/CCR2 pathway ameliorates the development of diabetic nephropathy. Biochemical and Biophysical Research Communications. 360(4). 772–777. 140 indexed citations
16.
Matsubara, Takeshi, Hideharu Abe, Hidenori Arai, et al.. (2006). Expression of Smad1 is directly associated with mesangial matrix expansion in rat diabetic nephropathy. Laboratory Investigation. 86(4). 357–368. 64 indexed citations
17.
Mima, Akira, Takeshi Matsubara, Hidenori Arai, et al.. (2006). Angiotensin II-dependent Src and Smad1 signaling pathway is crucial for the development of diabetic nephropathy. Laboratory Investigation. 86(9). 927–939. 68 indexed citations
18.
Nagai, Kojiro, Takeshi Matsubara, Akira Mima, et al.. (2005). Gas6 induces Akt/mTOR-mediated mesangial hypertrophy in diabetic nephropathy. Kidney International. 68(2). 552–561. 129 indexed citations
19.
Noda, Reiji, et al.. (2001). Evaluation of material recycling for plastics: environmental aspects. Journal of Material Cycles and Waste Management. 3(2). 118–125. 9 indexed citations
20.
Oga, Tatsuhide, Akio Ikeda, Takashi Nagamine, et al.. (2000). Implication of sensorimotor integration in the generation of periodic dystonic myoclonus in subacute sclerosing panencephalitis (SSPE). Movement Disorders. 15(6). 1173–1183. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Eric E. Simon Breakdown of academic impact, for papers by Kuolung Hu Breakdown of academic impact, for papers by Nagaraj Manickam Breakdown of academic impact, for papers by An-Hang Yang Breakdown of academic impact, for papers by Wen Si Breakdown of academic impact, for papers by Gustavo Aroca Breakdown of academic impact, for papers by Michael S. Balzer Breakdown of academic impact, for papers by Marcelino Bermúdez-López Breakdown of academic impact, for papers by Hermann Joseph Gröne Breakdown of academic impact, for papers by Fengxin Zhu
Rankless by CCL
2026